Changes

{{Under Construction}}

{{Under Construction}}

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-03. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].

<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|This page was converted to the new template on 2023-11-30. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].

Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others

Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others

__TOC__

__TOC__

==Cancer Category/Type==

==Cancer Category / Type==

Immunodeficiency-associated lymphoproliferative disorders

Immunodeficiency-associated lymphoproliferative disorders

|}         

|}         

              

              

==Individual Region Genomic Gain/Loss/LOH==

==Individual Region Genomic Gain / Loss / LOH==

Cytogenetic abnormalities are rare in P-PTLD. Trisomy X and trisomy 3 have been reported in the context of P-PTLD.  

Cytogenetic abnormalities are rare in P-PTLD. Trisomy X and trisomy 3 have been reported in the context of P-PTLD.  

|<ref name=":7" /><ref name=":6" />

|<ref name=":7" /><ref name=":6" />

|}

|}

==Gene Mutations (SNV/INDEL)==

==Gene Mutations (SNV / INDEL)==

The frequency of mutations in P-PTLD is lower, and variants seen are less deleterious, when compared to those seen in monomorphic PTLD. <ref>{{Cite journal|last=Menter|first=Thomas|last2=Juskevicius|first2=Darius|last3=Alikian|first3=Mary|last4=Steiger|first4=Juerg|last5=Dirnhofer|first5=Stephan|last6=Tzankov|first6=Alexandar|last7=Naresh|first7=Kikkeri N.|date=2017-04-17|title=Mutational landscape of B-cell post-transplant lymphoproliferative disorders|url=http://dx.doi.org/10.1111/bjh.14633|journal=British Journal of Haematology|volume=178|issue=1|pages=48–56|doi=10.1111/bjh.14633|issn=0007-1048}}</ref>  <ref>{{Cite journal|last=Butzmann|first=Alexandra|last2=Sridhar|first2=Kaushik|last3=Jangam|first3=Diwash|last4=Song|first4=Hanbing|last5=Singh|first5=Amol|last6=Kumar|first6=Jyoti|last7=Chisholm|first7=Karen M.|last8=Pinsky|first8=Benjamin|last9=Huang|first9=Franklin|date=2022-01-17|title=Mutations in JAK/STAT and NOTCH1 Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders|url=http://dx.doi.org/10.3389/fonc.2021.790481|journal=Frontiers in Oncology|volume=11|doi=10.3389/fonc.2021.790481|issn=2234-943X}}</ref> Mutations in BCL6 are reported in up to 50% of P-PTLD cases. <ref>{{Cite journal|last=Cesarman|first=E.|last2=Chadburn|first2=A.|last3=Liu|first3=Y. F.|last4=Migliazza|first4=A.|last5=Dalla-Favera|first5=R.|last6=Knowles|first6=D. M.|date=1998-10-01|title=BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome|url=https://pubmed.ncbi.nlm.nih.gov/9746767|journal=Blood|volume=92|issue=7|pages=2294–2302|issn=0006-4971|pmid=9746767}}</ref>

The frequency of mutations in P-PTLD is lower, and variants seen are less deleterious, when compared to those seen in monomorphic PTLD. <ref>{{Cite journal|last=Menter|first=Thomas|last2=Juskevicius|first2=Darius|last3=Alikian|first3=Mary|last4=Steiger|first4=Juerg|last5=Dirnhofer|first5=Stephan|last6=Tzankov|first6=Alexandar|last7=Naresh|first7=Kikkeri N.|date=2017-04-17|title=Mutational landscape of B-cell post-transplant lymphoproliferative disorders|url=http://dx.doi.org/10.1111/bjh.14633|journal=British Journal of Haematology|volume=178|issue=1|pages=48–56|doi=10.1111/bjh.14633|issn=0007-1048}}</ref>  <ref>{{Cite journal|last=Butzmann|first=Alexandra|last2=Sridhar|first2=Kaushik|last3=Jangam|first3=Diwash|last4=Song|first4=Hanbing|last5=Singh|first5=Amol|last6=Kumar|first6=Jyoti|last7=Chisholm|first7=Karen M.|last8=Pinsky|first8=Benjamin|last9=Huang|first9=Franklin|date=2022-01-17|title=Mutations in JAK/STAT and NOTCH1 Genes Are Enriched in Post-Transplant Lymphoproliferative Disorders|url=http://dx.doi.org/10.3389/fonc.2021.790481|journal=Frontiers in Oncology|volume=11|doi=10.3389/fonc.2021.790481|issn=2234-943X}}</ref> Mutations in BCL6 are reported in up to 50% of P-PTLD cases. <ref>{{Cite journal|last=Cesarman|first=E.|last2=Chadburn|first2=A.|last3=Liu|first3=Y. F.|last4=Migliazza|first4=A.|last5=Dalla-Favera|first5=R.|last6=Knowles|first6=D. M.|date=1998-10-01|title=BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome|url=https://pubmed.ncbi.nlm.nih.gov/9746767|journal=Blood|volume=92|issue=7|pages=2294–2302|issn=0006-4971|pmid=9746767}}</ref>

<nowiki>*</nowiki>''Citation of this Page'': “Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Polymorphic_lymphoproliferative_disorders_arising_in_immune_deficiency_/_dysregulation</nowiki>.[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases P]]

<nowiki>*</nowiki>''Citation of this Page'': “Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Polymorphic_lymphoproliferative_disorders_arising_in_immune_deficiency_/_dysregulation</nowiki>.

[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases P]]